NNC4004-0002

Phase 1Small molecule

Novo Nordisk

NNC4004-0002 is one of 12 small molecule programs targeting Hyperuricemia. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

HyperuricemiaRecruiting

HyperuricemiaPhase 1

Recruiting

Competition

Competitive Landscape

15 competitors in Hyperuricemia

#DrugCompanyPhaseTrials

Uloric

Takeda

Approved

11 2

Medrol

Farxiga

Alli

EEngelhard Arzneimittel GmbH & Co.KG

Approved

1 5

Tekturna

Tibotec Pharmaceuticals, Ireland

Approved

1 6

Decadron

AAspen Global Incorporated

Dotinurad

1 8

Alka-Seltzer

AAbbott

Preclinical

1 9

SHR4640

JJiangsu HengRui Medicine Co., Ltd.

Phase 2

5 10

NNC4004-0002

Novo Nordisk

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Hyperuricemia1 trial

A Research Study to Evaluate the Safety of NNC4004-0002 When Given to Participants With Asymptomatic Hyperuricemia

Recruiting· Novo Nordisk logo

Novo Nordisk·Phase 1·NCT06859073·60 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for NNC4004-0002. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — NNC4004-0002 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for NNC4004-0002. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Novo Nordisk company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: Novo Nordisk

NNC4004-0002

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Hyperuricemia1 trial

References

Drug Info

Quick Facts

Related News